Qiagen N.V. (QGEN)
45.53
-0.47 (-1.02%)
At close: Jan 14, 2025, 3:58 PM
45.64
0.24%
Pre-market Jan 15, 2025, 04:55 AM EST
undefined% (undefined)
| Bid | 45.65 |
| Market Cap | 10.10B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.46 |
| PE Ratio (ttm) | 98.98 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 45.69 |
| Volume | 519,981 |
| Avg. Volume (20D) | 857,644 |
| Open | 45.86 |
| Previous Close | 46.00 |
| Day's Range | 45.26 - 45.86 |
| 52-Week Range | 39.03 - 47.44 |
| Beta | undefined |
About QGEN
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology con...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Jun 28, 1996
Employees 5,800
Stock Exchange NYSE
Ticker Symbol QGEN
Website https://www.qiagen.com
Analyst Forecast
According to 8 analyst ratings, the average rating for QGEN stock is "Buy." The 12-month stock price forecast is $52, which is an increase of 14.21% from the latest price.
Buy 62.50%
Hold 37.50%
Sell 0.00%
Next Earnings Release
Qiagen N.V. is scheduled to release its earnings on Feb 4, 2025,
during market hours.
Analysts project revenue of $519.08M, reflecting a 1.95% YoY growth and earnings per share of 0.6, making a 9.09% increase YoY.
Analysts project revenue of $519.08M, reflecting a 1.95% YoY growth and earnings per share of 0.6, making a 9.09% increase YoY.
